Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rainer Storb

Showing results (281-290 of 315) with videos related to

Pageof 32
Sort By:
Cell Stem Cell|August 30, 2016
RNA Splicing Modulation Selectively Impairs Leukemia Stem Cell Maintenance in Secondary Human AMLLeslie A Crews, Larisa Balaian, Nathaniel P Delos Santos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2008
Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioningMohamed L Sorror, Barry E Storer, Brenda M Sandmaier, et al.
Blood|May 10, 2007
Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disordersChunkang Chang, Barry E Storer, Bart L Scott, et al.
Plos One|October 19, 2018
cGMP production of astatine-211-labeled anti-CD45 antibodies for use in allogeneic hematopoietic cell transplantation for treatment of advanced hematopoietic malignanciesYawen Li, Donald K Hamlin, Ming-Kuan Chyan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2005
Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donorsUte Hegenbart, Dietger Niederwieser, Brenda M Sandmaier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2006
Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantationFrédéric Baron, Rainer Storb, Barry E Storer, et al.
Blood|August 5, 2004
Duration of immunosuppressive treatment for chronic graft-versus-host diseaseBetty L Stewart, Barry Storer, Jan Storek, et al.
Bone Marrow Transplantation|September 5, 2019
Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experienceMazyar Shadman, David G Maloney, Barry Storer, et al.
Haematologica|August 3, 2014
A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantationBrian Kornblit, David G Maloney, Barry E Storer, et al.
Cancer|July 25, 2015
Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioningJennifer E Vaughn, Mohamed L Sorror, Barry E Storer, et al.
Pageof 32

Showing results (281-290 of 315) with videos related to

Sort By:
Pageof 32
Cell Stem Cell|August 30, 2016
RNA Splicing Modulation Selectively Impairs Leukemia Stem Cell Maintenance in Secondary Human AMLLeslie A Crews, Larisa Balaian, Nathaniel P Delos Santos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2008
Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioningMohamed L Sorror, Barry E Storer, Brenda M Sandmaier, et al.
Blood|May 10, 2007
Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disordersChunkang Chang, Barry E Storer, Bart L Scott, et al.
Plos One|October 19, 2018
cGMP production of astatine-211-labeled anti-CD45 antibodies for use in allogeneic hematopoietic cell transplantation for treatment of advanced hematopoietic malignanciesYawen Li, Donald K Hamlin, Ming-Kuan Chyan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2005
Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donorsUte Hegenbart, Dietger Niederwieser, Brenda M Sandmaier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2006
Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantationFrédéric Baron, Rainer Storb, Barry E Storer, et al.
Blood|August 5, 2004
Duration of immunosuppressive treatment for chronic graft-versus-host diseaseBetty L Stewart, Barry Storer, Jan Storek, et al.
Bone Marrow Transplantation|September 5, 2019
Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experienceMazyar Shadman, David G Maloney, Barry Storer, et al.
Haematologica|August 3, 2014
A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantationBrian Kornblit, David G Maloney, Barry E Storer, et al.
Cancer|July 25, 2015
Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioningJennifer E Vaughn, Mohamed L Sorror, Barry E Storer, et al.
Pageof 32